Literature DB >> 22438180

Smith-Lemli-Opitz syndrome: Objective assessment of facial phenotype.

Małgorzata J M Nowaczyk1, Mattea Tan, Jemila S Hamid, Judith E Allanson.   

Abstract

Smith-Lemli-Opitz syndrome (SLOS), is an autosomal recessive condition caused by cholesterol synthesis deficiency which results in a wide phenotypic spectrum which includes multiple malformations, distinctive facial appearance, and intellectual disability. This anthropometric and observational study was carried out to define the key facial characteristics of individuals with SLOS and to evaluate evolution of the facial phenotype with age. Clinical photographs were obtained on 51 subjects with SLOS and standardized facial anthropometry was performed on 42; the ages ranged from 6 months to 20 years. For each individual, 22 standardized cranial and facial measurements were obtained and compared to published age- and sex-matched controls. Craniofacial pattern profiles were compared between sexes, various age groups, plasma cholesterol concentration at the time of diagnosis, and physical severity score. Mean-Z, a measurement of overall facial size, and craniofacial variability index (CVI), a summary anthropometric measure of craniofacial deviation from the norm, were calculated and compared according to methods published previously. A characteristic craniofacial pattern profile was universally present: narrow forehead, brachycephaly, short palpebral fissures, short nasal ridge, anteverted nares, flat face, normal jaw width, and retrognathia. The facial measurements of subjects with SLOS had higher deviations from the norm with mean CVI of 2.11; SD = 0.47 (controls: Mean = 0.76, SD = 0.19; <0.0001) than age- and sex-matched controls. Their faces were also smaller than controls: 70% of subjects had mean-Z values 2 SD below the mean for controls; average Z-score was -1.64; SD = 0.85 (controls: mean = 0, SD = 0.64; <0.0001). There were no significant differences in the craniofacial pattern profile between the sexes or clinical severity as measured by either plasma cholesterol level at the time of diagnosis or the physical severity score. Patients with a lower weight at the time of assessment and patients with higher physical severity score had higher CVI measures (P < 0.001 and P < 0.002, respectively), suggesting that the degree of deviation from craniofacial norms is a function of the overall physical severity.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22438180     DOI: 10.1002/ajmg.a.35285

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

1.  Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease.

Authors:  Frances M Platt; Christopher Wassif; Alexandria Colaco; Andrea Dardis; Emyr Lloyd-Evans; Bruno Bembi; Forbes D Porter
Journal:  Annu Rev Genomics Hum Genet       Date:  2014       Impact factor: 8.929

2.  Birthday of a syndrome: 50 years anniversary of Smith-Lemli-Opitz Syndrome.

Authors:  Martina Witsch-Baumgartner; Barbara Lanthaler
Journal:  Eur J Hum Genet       Date:  2014-05-14       Impact factor: 4.246

3.  Statins for Smith-Lemli-Opitz syndrome.

Authors:  Rami A Ballout; Simona Bianconi; Alicia Livinski; Yi-Ping Fu; Alan T Remaley; Forbes D Porter
Journal:  Cochrane Database Syst Rev       Date:  2020

4.  Altered cerebrospinal fluid proteins in Smith-Lemli-Opitz syndrome patients.

Authors:  Stephanie M Cologna; Christine Shieh; Cynthia L Toth; Antony Cougnoux; Kathryn R Burkert; Simona E Bianconi; Christopher A Wassif; Forbes D Porter
Journal:  Am J Med Genet A       Date:  2016-05-05       Impact factor: 2.802

5.  Pathogenesis, Epidemiology, Diagnosis and Clinical Aspects of Smith-Lemli-Opitz Syndrome.

Authors:  Simona E Bianconi; Joanna L Cross; Christopher A Wassif; Forbes D Porter
Journal:  Expert Opin Orphan Drugs       Date:  2015-03       Impact factor: 0.694

6.  Auditory phenotype of Smith-Lemli-Opitz syndrome.

Authors:  Christopher K Zalewski; Sarah A Sydlowski; Kelly A King; Simona Bianconi; An Dang Do; Forbes D Porter; Carmen C Brewer
Journal:  Am J Med Genet A       Date:  2021-02-02       Impact factor: 2.578

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.